HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

III-10

a differentiation inducer; structure in first source

Networked: 4 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Pyrans: 130
    - Benzopyrans: 195
      - Chromones: 159
        Flavonoids: 9773
        Flavones: 446
        III-10: 4
  - Pyrrolidines: 115
    - III-10: 4
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Benzopyrans: 195
      - Chromones: 159
        Flavonoids: 9773
        Flavones: 446
        III-10: 4

Experts

1.	Li, Zhiyu: 2 articles (10/2015 - 04/2012)
2.	Lu, Na: 2 articles (10/2015 - 04/2012)
3.	Song, Bao-An: 1 article (02/2016)
4.	Wang, Pei-Yi: 1 article (02/2016)
5.	Wu, Zhi-Bing: 1 article (02/2016)
6.	Xue, Wei: 1 article (02/2016)
7.	Yang, Song: 1 article (02/2016)
8.	Zhou, Jian: 1 article (02/2016)
9.	Zhou, Lei: 1 article (02/2016)
10.	Dai, Qinsheng: 1 article (10/2015)

Related Diseases

1.	Hepatocellular Carcinoma (Hepatoma) 10/05/2015 - "In this study, we demonstrated that III-10 induced cell apoptosis in human hepatocellular carcinoma cells. " 10/05/2015 - "III-10, a newly synthesized flavonoid, induces cell apoptosis with the involvement of reactive oxygen species-mitochondria pathway in human hepatocellular carcinoma cells."
2.	Leukemia 04/11/2012 - "To investigate whether III-10 could express anticancer effect on human U937 leukemia cells through differentiation induction, a series of experiments were processed. " 04/11/2012 - "III-10, a newly synthesized flavonoid, induced differentiation of human U937 leukemia cells via PKCδ activation." 10/05/2015 - "We recently established that III-10, a new flavonoid with a pyrrolidinyl and a benzyl group substitution, exerted its anti-tumor effect via inducing differentiation of human U937 leukemia cells. "
3.	Neoplasms (Cancer) 10/05/2015 - "We recently established that III-10, a new flavonoid with a pyrrolidinyl and a benzyl group substitution, exerted its anti-tumor effect via inducing differentiation of human U937 leukemia cells. "
4.	Renovascular Hypertension (Goldblatt Syndrome) 06/01/2008 - "We allocated 40 male Wistar rats with 2-kidney, 1-clip renovascular hypertension (2K1C-RVH) to 4 groups (each n = 10) that were dialyzed using various solutions for 42 days as follows: Group I-10 mL pH 3.5 dialysis solution containing 1.35% glucose Group II-10 mL pH 3.5 dialysis solution, plus oral administration of CS866 5 mg/kg daily Group III-10 mL pH 3.5 dialysis solution, plus oral administration of the calcium channel blocker (CCB) amlodipine 3 mg/kg daily Group IV-10 mL pH 7.0 dialysis solution Dialysis solution was injected every day for 42 days. "
5.	Bacterial Infections (Bacterial Infection) 02/15/2016 - "Among them, I-8, I-10, I-12, II-10, II-12, III-10, and III-12 exert excellent inhibition activities against the three pathogenic bacteria with the half-maximal effective concentration (EC50) values ranging from 0.54 to 12.14 μg/mL. Our results demonstrate that pyridinium-tailored 1,3,4-oxadiazole thioether/sulfoxide/sulfone derivatives can serve as potential alternative bactericides for the management of plant bacterial diseases."

Related Drugs and Biologics

1.	Flavonoids
2.	Reactive Oxygen Species (Oxygen Radicals)
3.	Amlodipine (Norvasc)
4.	Dialysis Solutions
5.	Sulfones
6.	Sulfides (Thioethers)
7.	Glucose (Dextrose)
8.	Calcium Channel Blockers (Blockers, Calcium Channel)
9.	Olmesartan Medoxomil (Votum)
10.	1,3,4-oxadiazole

Related Therapies and Procedures

1.	Oral Administration